SAN DIEGO--(BUSINESS WIRE)--Ardea Biosciences, Inc. (Nasdaq:RDEA) today announced positive results from a Phase 1 study in normal, healthy volunteers of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and a pilot Phase 2a proof-of-concept study in gout patients of RDEA594’s prodrug, RDEA806 (RDEA806 is converted to RDEA594 in the body). RDEA594 is an inhibitor of URAT1, a transporter in the kidney that regulates uric acid excretion. These data, as well as future development plans for RDEA594, are being presented today at an investor and analyst event hosted by the Company in New York, NY. The Company intends to present further data from RDEA594 studies at an upcoming scientific conference.
